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Abstract
Purpose: This is the first clinical evaluation of a novel fluorescent imaging agent (Omocianine)
for breast cancer detection with diffuse optical tomography (DOT).
Procedures: Eleven women suspected of breast cancer were imaged with DOT at multiple time
points (up to 24 h) after receiving an intravenous injection of Omocianine (doses 0.01 to 0.1 mg/kg
bodyweight). Breast MRI was obtained for comparison.
Results: Histopathology showed invasive cancer in ten patients and fibroadenoma in one
patient. With the lowest dose of Omocianine, two of three lesions were detected; with the second
dose, three of three lesions were detected; with the two highest doses, none of five lesions were
detected. Lesion location on DOT showed excellent agreement with MRI. Optimal lesion-to-
background signals were obtained after 8 h. No adverse events occurred.
Conclusions: Lowest doses of Omocianine performed best in lesion detection; DOT using a low-
dose fluorescent agent is feasible and safe for breast cancer visualization in patients.
Key words: Diffuse optical tomography, Fluorescence, Breast cancer, Detection, Contrast
agent, Molecular imaging
Introduction
O
ptical breast imaging is a novel imaging technique that
uses near-infrared (NIR) light to assess optical proper-
ties of tissue and is expected to play an important role in
breast cancer detection. It dates back to 1929 when Cutler
[1] investigated the shadows of light transmitted through the
breast. Although large, highly vascular, malignant lesions
could be detected, the method did not achieve sufficient
sensitivity and specificity to be used in clinical practice at
the time. During the last decade, progress in source and
detector technology, light propagation modeling, and poten-
tial fluorescent contrast agents has resulted in a renewed
interest in optical imaging [2]. Optical breast imaging uses
NIR light in the wavelength range of 650 to 1,000 nm to
assess optical properties of tissue. Functional information of
tissue components, i.e., absorption characteristics of oxy-
and deoxyhemoglobin, water, and lipid, can be obtained by
combining images acquired at various wavelengths. Until
now, studies have focused on using the intrinsic optical
properties of the breast to visualize lesions without the use of
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absorption for carcinomas than for the surrounding paren-
chyma due to increased blood content associated with
angiogenesis [3–11]. However, intrinsic contrast alone is
probably not sensitive enough for (early) lesion detection
[12]. Optical breast imaging using a fluorescent contrast
agent may improve lesion contrast and can potentially detect
changes in breast tissue earlier. When fluorescent probes are
excited by NIR light, they emit photons at predefined
wavelength ranges, detectable by an optical imaging system.
The fluorescent probes can either bind specifically to certain
targets associated with cancer or can non-specifically
accumulate at the tumor site, mostly by extravasation
through leaky vessels. Several of these probes have already
been tested successfully in animal experiments [13–15].
Major advantages of optical imaging with fluorescent probes
are that it does not use any radioactive components (as in
PET and SPECT) and that its sensitivity is very high
(nanomolar to picomolar concentration range) compared to
MRI. This technique has great potential in early breast
cancer detection since in vivo imaging of molecular changes
associated with breast cancer formation is technically
feasible. Optical breast imaging provides us with functional
information of the tissue, in contrast to X-ray mammography
which merely relies on structural information. Additional
advantages are that it uses no ionizing radiation, it is
relatively inexpensive, which can result in repeated use even
in young women, and is easily accessible. However, this
technique is still in a very early phase of development.
Systems need to be thoroughly evaluated first before the
diagnostic value of the technique in a clinical setting can be
determined. Few studies reported on optical breast imaging
with the use of a fluorescent contrast agent. Two case reports
described their experiences using the non-specific agent
Indocyanine Green (ICG), the only fluorescent agent
approved for use in humans today [16, 17]. Both groups
observed a marked absorption increase in the malignant
tumors due to accumulation of ICG, which, besides its
fluorescent characteristics, also acts as a light absorber. In
addition, differences in pharmacokinetics between malignant
and benign lesions were found. However, ICG character-
istics are suboptimal for fluorescence optical breast imaging;
in particular, the low fluorescence quantum yield is a
problem [18]. Nevertheless, in the study by Corlu et al.
[19], it was shown that the use of ICG is feasible for
fluorescence diffuse optical tomography (DOT). This was
the first and thus far the only study to demonstrate
fluorescence DOT in vivo in three women with breast
cancer.
In our study, we investigated a non-specific cyanine-
based fluorescent dye (Omocyanine) in patients using a
DOT system dedicated for breast imaging. The aim of this
study was to evaluate if our DOT system could detect
malignant breast lesions using this new dye and to assess
diagnostic efficacy, target dose, imaging window, and safety
of the fluorescent contrast agent.
Methods
Patients
A total of 12 women (mean age 54, range 23–81) diagnosed with a
1- to 5-cm BI-RADS 4/5 breast lesion on X-ray mammography
were prospectively included at the University Medical Center
Utrecht, The Netherlands between January and July 2007.
Additional to the normal clinical diagnostic procedure of
mammography and ultrasound, patients underwent optical imaging
at different time points and received a single intravenous admin-
istration of the fluorescent contrast agent. MRI was obtained in all
patients for comparison.
For every patient, the study consisted of a screening period to
verify inclusion criteria, an imaging period during which optical
images were acquired and the study drug was administered, and a
follow-up period of 1 week to monitor adverse events.
Patients were excluded from the study if they were clinically
unstable, had severe renal or hepatic problems, had a history of
anaphylactic reactions, were pregnant or lactating, had more than
two lesions in the ipsilateral breast, or if they underwent a breast
biopsy less than 6 months before the study.
The study protocol was approved by the ethics committee of the
University Medical Center Utrecht, The Netherlands, and written
informed consent was obtained from all patients.
Contrast Material and Administration
As study drug, a single intravenous injection of Omocyanine
(Bayer Schering Pharma, Berlin, Germany) suspended in saline
(1 mg/mL) was used. Doses of 0.01, 0.02, 0.05, and 0.1 mg/kg
body weight were administered in a dose escalating scheme with
three patients per dose level, starting at the lowest dose. All doses
were administered intravenously at a rate of 1 mL/s by manual
injection, followed by a saline flush of 10–20 mL.
Before the injection of the study drug, baseline optical images
were acquired for both breasts. After injection, optical images were
acquired up to 24 h, with, respectively, eight and five imaging time
points for the ipsilateral and contralateral breast (see flowchart in
Fig. 1).
Safety Evaluations
Standard safety procedures (physical examinations, ECG record-
ings, laboratory tests) were carried out up to 24 h after study drug
administration. Adverse events were recorded starting at the
moment of study drug administration and throughout the 1-week
follow-up period. Adverse events were defined as untoward
medical occurrences which are not necessarily causally related to
the drug administration. Signs and symptoms present before the
study drug administration were recorded as baseline findings.
Optical Imaging
Data Acquisition DOT scans were performed on a Philips
Diffuse Optical Tomography system (Philips Healthcare, Best,
The Netherlands). A patient was placed in the prone position on the
system bed with one breast suspended in the cup [20]. The
scanning module of the DOT system consists of a cup with a total
of 507 optical fibers mounted on the surface. The 253 source fibers
on all sides of the cup are connected to a fiber switch to direct the
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fibers are interleaved with 254 detector fibers connected to 254
detectors. For each scan, the cup was filled with a matching fluid
that has optical properties approximately equal to those of the
average breast. This matching fluid enables a stable optical
coupling between the fibers and the breast, as well as eliminating
optical shortcuts of the diffuse light around the breast. During
imaging, the breast was sequentially illuminated with continuous-
wave near-infrared light from all source positions. Light emanating
from the breast was detected for each source position by the
detector fibers on all sides of the cup. Images were obtained at four
discrete wavelengths (690, 730, 780, and 850 nm). Each breast is
scanned separately. During one scan, the system was operated in
two modes: transmission and fluorescence modes. The transmission
measurements aimed at getting information on the optical absorp-
tion and scattering properties of the breast at four wavelengths. The
fluorescent measurements were performed at one wavelength
(730 nm) and the fluorescent signal was detected at a different
wavelength (>750 nm), while the laser light was blocked by filters
in the detection path. These measurements aimed at getting
information on the concentration and distribution of the fluorescent
dye in the breast.
The duration of the examination was approximately 1 min per
wavelength and 5 min for the fluorescence, for a total of 9 min per
breast.
Image Reconstruction After optical data acquisition, three-
dimensional absorption images were reconstructed by a linear
reconstruction algorithm based on the Rytov approximation [21].
For reconstruction of three-dimensional fluorescence images, an
algorithm based on the Born approximation was used [22]. One
absorption image was calculated for each wavelength (four per
scan). Since the reconstruction algorithm assumes constant scatter-
ing throughout the measurement cup, there is an influence of
scattering variations on the reconstructed absorption images. If the
average scattering of the breast is different from the scattering of
the fluid, there will be an offset on the reconstructed breast
absorption. If there is a variation of the scattering within the breast,
the reconstructed image also shows features due to these variations.
The fluorescence images (one per scan) only show fluorescence
signal coming from the injected contrast agent; no absorption
information is displayed in these images.
Magnetic Resonance Imaging
Contrast-enhanced breast MRI was performed on a 3.0-T clinical
MR system (3.0 T Achieva, Philips Healthcare). Patients were
placed in prone position on a dedicated four-element SENSE
compatible phased-array bilateral breast coil (MRI devices, Würz-
burg, Germany) that was utilized for simultaneous imaging of both
breasts. The scan protocol included an axial high-resolution T1-
weighted fast gradient echo (HR-T1FFE) fat-suppressed series (TE/
TR 1.7/4.5 ms; inversion delay SPAIR 130 ms; flip angle 10°; FOV
340×340 mm
2, acquired voxel size 0.66×0.66×1.6 mm
3, recon-
structed voxel size 0.66×0.66×0.80 mm
3), followed by an axial
T2-weighted fat suppressed series (TE/TR 120/9,022 ms; inversion
delay SPAIR 125 ms; flip angle 90°; FOV 340×340 mm
2, acquired
voxel size 1.01×1.31×2.0 mm
3, reconstructed voxel size 0.66×
0.66×2.00 mm
3). Finally, dynamic contrast-enhanced fat-sup-
pressed T1-weighted images (TE/TR 1.3/3.4 ms; flip angle 10°;
FOV 320×320 mm, acquired voxel size 0.91×0.91 mm×2.00 mm,
reconstructed voxel size 0.83×0.83 mm×1.00 mm; dynamic scan
duration 60 s) were acquired, starting after intravenous bolus
injection of 0.1 mmol/kg gadolinium (Magnevist, Bayer Schering
Pharma).
Image Interpretation
MRI data were used as a benchmark for the optical image
interpretation because these provide three-dimensional anatomical
information.
When an enhanced fluorescent signal was visible on the optical
images,its location was always compared to the position on MRI to see
if the optical signal matched with the lesion location as seen on MRI.
A region of interest (ROI) was drawn at a single slice of the
lesion site location for all fluorescent images over time. Separate
ROIs were drawn for each imaging time point, each time matching
the location of the lesion with the MRI data. For comparison, a
similar ROI was drawn for each time point at the mirror image
lesion site location of the contralateral breast where no lesion was
found. The visibility of the lesions on DOT was assessed
quantitatively by the DOT system. For all the ROIs that were
drawn, quantitative values were computed from the images of the
optical absorption coefficient obtained from the DOT system. The
mean fluorescence intensity of the ROIs was determined. To
calculate the lesion-to-background ratio, this value was divided by
the mean fluorescence of the background, which included the rest
of the breast on that slice except for the lesion and the nipple (very
high intensity). The same was done for the mirror image ROI to
compare the values in the ipsilateral and contralateral breast.
Absorption images obtained before contrast administration were
also assessed for lesion visibility; lesion-to-background ratios were
calculated in the same way as for the fluorescence images in the
cases that an enhanced fluorescent signal was observed.
To assess the pharmacokinetics of the new contrast agent in the
breast, the uptake over time was compared quantitatively on the
fluorescence images for the different ROIs in the ipsilateral and
contralateralbreast,andtheoptimalimagingtimepointwasestimated.
The reference standard for final diagnosis of the lesions was
histopathology after surgery or large core needle biopsy.
Statistics
To assess whether lesion size and administered dose were different
between the lesions detected with DOT and the lesions not detected
Fig. 1. Flowchart of the study’s imaging period.
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package SPSS version 15.0 (SPSS Inc., Chicago, IL, USA) was
used for all statistical computations.
Results
Twelve women suspected of breast cancer were included in
this study. One patient was excluded after screening
measurements due to severe renal failure and therefore did
not receive the contrast agent or the optical measurements.
Eleven patients (mean age 54, range 23–81) underwent the
total study procedures. Of these patients, histopathology
results of the breast lesions showed invasive ductal carci-
noma in eight patients (median lesion diameter 21 mm),
invasive lobular carcinoma in two patients (median lesion
diameter 40 mm), and a benign fibroadenoma (lesion
diameter 15 mm) in one patient (Table 1).
In the lowest dose group, lesions were detected in two
patients on the fluorescence DOT images. In the second dose
Table 1. Overview of study results per patient
Patient Age Contrast agent dose (mg/kg) Lesion type Lesion diameter on MRI (mm) Detected by DOT
1 48 0.01 IDC 25 No
a
2 81 0.01 ILC 29 Yes
3 59 0.01 IDC 18 Yes
4 74 0.02 IDC 24 Yes
5 40 0.02 IDC 74 Yes
6 55 0.02 IDC 34 Yes
7 47 0.05 IDC 14 No
8 23 0.05 FA 15 No
9 62 0.05 IDC 14 No
10 51 0.1 ILC 51 No
a
11 55 0.1 IDC 13 No
IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, FA fibroadenoma
aIn these cases, the lesion was located close to the patient’s chest wall and physically too far above the upper optical fibers in the cup to be measured by the
current DOT system
Fig. 2. Example of the fluorescent images in a patient with invasive lobular carcinoma in the left breast (diameter 2.5 cm),
optical images obtained 1, 2, 4, 8, and 24 h after fluorescent contrast agent injection. Contralateral and ipsilateral breast are
shown, the lesion is indicated by the arrows, nipple is encircled, some reconstruction artifacts are visible in the top middle of
the images. MRI is shown for comparison. The grayscale of the optical images is adjusted individually for each image to range
from zero to five times the average background value. In this way, the varying contrast between lesion and background in the
ipsilateral breast is visible.
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were detected in the two highest dose groups. In total, five of
the ten malignant lesions (50%) were visualized by DOT
using the fluorescent contrast agent. The locations of lesions
detected with DOT showed excellent agreement with MRI.
Lesion location on the optical images was reproducible over
time (Fig. 2). Optimal lesion-to-background signals were
obtained after 8 h, ranging from 1.8 to 2.8 for the detected
lesions. Non-specific fluorescent enhancement of glandular
tissue was clearly visible on all optical fluorescence images,
starting after 30 min and still evident 24 h later (Fig. 2).
Contrast agent signal evidently increased with dose. Higher
concentrations were problematic for the reconstruction
algorithm due to the absorption of the agent being no longer
negligible compared to the tissue absorption, an important
assumption of the algorithm. A trend in the direction of a
lower administered contrast agent dose was found for the
detected lesions (exact p value 0.052). Median diameter was
larger for the detected lesions (29 mm) than for the non-
detected lesions (14.5 mm), but this difference was not
significant (exact p value 0.13).
The absorption images obtained with DOT before the
contrast administration showed higher attenuation in the
lesions than in the surrounding normal parenchyma. Mean
lesion-to-background ratios were 1.8, 2.6, 1.6, and 1.4 for
the wavelengths 690, 730, 780, and 850 nm, respectively.
Safety
No adverse events related to the study drug were observed
during this study.
Discussion
The current study shows that DOT using a low dose of the
fluorescent agent Omocyanine is feasible and safe for breast
cancer visualization in patients. To our knowledge, this is
the first report of the use of a novel fluorescent contrast
agent for optical imaging of the breast in women suspected
of breast cancer.
The fluorescent signal emitted by the contrast agent after
excitation by NIR light could be detected with our DOT
system in all patients. Since four different dose levels of the
fluorescent agent were administered (ranging from 0.01 to
0.1 mg/kg body weight), the absolute increase of fluores-
cence signal with higher doses of the contrast agent could be
clearly observed. Corlu et al. [19] were the first to
demonstrate fluorescence DOT in patients using ICG. Other
investigators did not use the fluorescence, but the absorb-
ance characteristics of ICG for their optical imaging
technique [16, 17]. In contrast to Corlu et al., we did not
only investigate the breast with the lesion but also the
contralateral healthy breast to obtain more information on
the specificity of the technique.
In the present study, five of ten malignant lesions could
be detected by fluorescence DOT. Best lesion-to-background
ratios (range 1.8–2.8) were obtained after 8 h. Limitations in
lesion detection primarily resulted from the reconstruction
algorithm and the cup geometry of the current DOT system.
Lowest doses of Omocyanine performed best in lesion
detection, while higher concentrations were problematic for
the reconstruction algorithm. The reason was that at a higher
dose level, the contrast agent absorption was no longer
Fig. 3. Dye uptake over time for patient 2 and patient 5. The
dye kinetics for patient 2 with mainly fatty breast tissue (BI-
RADS density category 1) show lower uptake (reconstructed
fluorescence signal) of the mirror image vs. the lesion, while
for patient 5 with more glandular breast tissue (BI-RADS
density category 3), the dye kinetics show similar uptake of
the mirror image vs. the lesion.
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important assumption of the algorithm. Even at later imaging
time points (up to 24 h), this reconstruction problem
persisted due to the slow washout of the contrast agent. In
two patients, the lesions were located close to their chest
walls and could not be measured by the DOT system. Most
probably, during the optical scans, these lesions were
physically located too far above the upper optical fibers in
the cup to influence the light pathways. Advances in cup
geometry are feasible and should be realized to improve
visualization of these lesions.
The other important limitation in this study was that
Omocyanine is a non-specific contrast agent. Ideally, this
fluorescent probe would accumulate at the tumor site by
extravasation through leaky vessels. However, since it does
not specifically bind to a cancer-associated target, enhancement
of other normal tissues is also possible. This non-specific
enhancement pattern was observed when comparing the uptake
of the contrast agent over time for the lesion and mirror images
in different patients. Differences were noted between patients
whose breasts contained mostly fatty tissue and patients whose
breasts contained mostly glandular (heterogeneously dense)
tissue. To illustrate this observation, two examples are shown in
Fig. 3. As shown in the graphs, uptake of the contrast agent was
much lower in fatty tissue (patient 2) than in glandular tissue
(patient5)ifthelesioniscomparedtothemirrorimagelocation.
In the patients with a high content of glandular tissue in their
breasts, the uptake at the mirror image site vs. the background
was quite similar to the uptake at the lesion site vs.t h e
background. Although the sample size is small and we should
be cautious in generalizing these observations, it indicates that
the distinction between glandular and malignant tissue could be
problematic with this non-specific fluorescent contrast agent.
Clearly, there is a need for target-specific fluorescent agents to
be tested in patient studies using an optical imaging device.
In the absorption mode, DOT showed around twofold
higher absorption at the site of the malignant lesions using
wavelengths 690 and 730 nm, which is in agreement with
previous studies and probably related to increased light
absorption by the tumors’ higher hemoglobin content due to
angiogenesis [7–9, 11, 19, 23].
To gain more insight in the composition of the breast, i.e.,
determine relative concentrations of (de)oxyhemoglobin, fat,
and water, a spectral analysis which combines data of the
different wavelengths in one model could be performed.
Potentially, this spectral absorption information could
improve the identification of malignant lesions and the
specificity of DOT.
In conclusion, in this first feasibility study, we have
shown that diffuse optical tomography with the use of the
fluorescent contrast agent Omocyanine has the potential to
safely visualize malignant breast tumors in patients. Devel-
opment and especially the clinical translation of fluorescent
probes with specific binding affinity for relevant molecular
targets will be crucial to translate molecular breast imaging
to clinical applications.
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